



# INVESTOR PRESENTATION

March 2022

---

**Accelerating MIS Spine**

Culture | Technology | Accessibility

# DISCLAIMER AND CONFIDENTIALITY NOTICE



In this presentation, “Accelus”, the “Company”, “we”, “us” and “our” mean Integrity Implants Inc. d/b/a Accelus. All amounts are in U.S. dollars unless otherwise indicated. The information contained herein does not purport to contain all of the information about the Company or CHP Merger Corp. (“CHP”). The information contained herein has not been independently verified.

In connection with the proposed business combination, CHP intends to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which will include a preliminary proxy statement/prospectus and a definitive proxy statement/prospectus, and other related documents. CHP’s stockholders are advised to read, when available, the proxy statement/prospectus included in the Registration Statement, including any amendments thereto, as well as other documents filed with the SEC in connection with the proposed business combination. After the Registration Statement is declared effective, the definitive proxy statement/prospectus and other relevant materials will be mailed to stockholders of CHP as of a record date to be established for voting on the proposed business combination and other matters as may be described in the Registration Statement. Stockholders will be able obtain copies of the preliminary proxy statement/prospectus, the definitive proxy statement/prospectus, and other documents filed with the SEC that will be incorporated by reference therein, without charge, once available, at the SEC’s website at [www.sec.gov](http://www.sec.gov), or by directing a request to: CHP Merger Corp., 25 Deforest Avenue, Suite 108, Summit, NJ 07901

CHP, Accelus and their respective directors and executive officers may be deemed participants in the solicitation of proxies from CHP’s stockholders with respect to the business combination. A list of the names of those directors and executive officers and a description of their interests in CHP will be contained in the Registration Statement when available.

No representations or warranties are made or implied with respect to the information contained herein. This presentation contains forward-looking statements with respect to the Company. These forward-looking statements, by their nature, require the Company to make certain assumptions and necessarily involve known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied in these forward-looking statements, including without limitation the successful and timely completion and the commercialization of the products referred to herein. Forward-looking statements are not guarantees of performance. These forward-looking statements, including financial outlooks and strategies or deliverables stated herein, may involve, but are not limited to, comments with respect to the Company’s business or financial objectives, its strategies or future actions, its projections, targets, expectations for financial condition or outlook for operations. Words such as “may”, “will”, “would”, “could”, “expect”, “believe”, “plan”, “anticipate”, “intend”, “estimate”, “continue”, or the negative or comparable terminology, as well as terms usually used in the future and conditional, are intended to identify forward-looking statements. Information contained in forward-looking statements is based upon certain material assumptions that were applied in drawing a conclusion or making a forecast or projection, including perceptions of historical trends, current conditions and expected future developments, as well as other considerations that are believed to be appropriate in the circumstances. These assumptions are considered to be reasonable based on currently available information, but the reader is cautioned that these assumptions regarding future events, many of which are beyond its control, may ultimately prove to be incorrect since they are subject to risks and uncertainties that affect the Company and its business. The forward-looking information set forth therein reflects expectations as of the date hereof and is subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Undue reliance should not be placed on forward-looking statements. The forward-looking statements contained in this presentation are expressly qualified by this cautionary statement. This presentation is not intended to form the basis of any investment decision and there can be no assurance that any transaction will be undertaken or completed in whole or in part. The delivery of this presentation shall not be taken as any form of commitment on the part of the Company or its shareholders to proceed with any transaction, and no offers will subject the Company or its shareholders to any contractual obligations before definitive documentation has been executed. The Company reserves the right at any time without prior notice and without any liability to (i) negotiate with one or more prospective investors in accordance with any timetable and on any terms that the Company may decide, (ii) provide different information or access to information to different prospective investors, (iii) enter into definitive documentation and (iv) terminate the process, including any negotiations with any prospective investor without giving any reasons therefor.

This presentation does not constitute (i) a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed business combination or (ii) an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of CHP, the Company, or any of their respective affiliates. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.



# DISCLAIMER AND CONFIDENTIALITY NOTICE

This presentation includes certain financial measures not presented in accordance with GAAP. These non-GAAP financial measures are not measures of financial performance in accordance with GAAP and may exclude items that are significant in understanding and assessing the Company's financial results. Therefore, these measures should not be considered in isolation or as an alternative to net income, cash flows from operations or other measures of profitability, liquidity or performance under GAAP. You should be aware that the Company's presentation of these measures may not be comparable to similarly-titled measures used by other companies. The Company believes these non-GAAP measures of financial results provide useful information to management and investors regarding certain financial and business trends relating to the Company's financial condition and results of operations. The Company believes that the use of these non-GAAP financial measures provides an additional tool for investors to use in evaluating ongoing operating results and trends in and in comparing the Company's financial measures with other similar companies. These non-GAAP financial measures are subject to inherent limitations as they reflect the exercise of judgments by management about which expense and income items are excluded or included in determining these non-GAAP financial measures.

This presentation also includes certain projections of non-GAAP financial measures. Due to the high variability and difficulty in making accurate forecasts and projections of some of the information excluded from these projected measures, together with some of the excluded information not being ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measures without unreasonable effort. Consequently, no disclosure of estimated comparable GAAP measures is included and no reconciliation of the forward-looking non-GAAP financial measures is included. In addition, these non-GAAP financial measures may be calculated or presented differently than, and may not be comparable to, non-GAAP financial measures disclosed by other companies. This presentation contains forecasts with respect to the Company's projected financial results, including Revenue and CAGR, for the Company's fiscal years 2021 through 2025, and the data presented for the fiscal year 2020 is derived from unaudited financials. The Company's independent auditors have not audited, reviewed, compiled or performed any procedures with respect to the projections for the purpose of their inclusion in this presentation, and accordingly, they did not express an opinion or provide any other form of assurance with respect thereto for the purpose of this presentation. These projections should not be relied upon as being necessarily indicative of future results. The assumptions and estimates underlying the prospective financial information are inherently uncertain and are subject to a wide variety of significant business, economic and competitive risks and uncertainties that could cause actual results to differ materially from those contained in the prospective financial information. Accordingly, there can be no assurance that the prospective results are indicative of the future performance of the Company or that actual results will not differ materially from those presented in the prospective financial information or that the prospective financial information will be the same as that presented in future public filings related to the business combination. Inclusion of the prospective financial information in this presentation should not be regarded as a representation by any person that the results contained in such prospective financial information will be achieved. This presentation contains confidential information pertaining to the business, operations, and assets of the Company and the use hereof is governed by the confidentiality agreement ("CA") or non-disclosure agreement ("NDA") that has been executed by each recipient. If you are in possession of this presentation, you should familiarize yourself with such CA or NDA before reading, circulating, disclosing or using the presentation. If you have not executed and delivered, or are otherwise not bound by such CA or NDA, you have received this presentation in error. If so, please do not copy or distribute the presentation and return the presentation to the sender hereof.

This presentation includes market and industry data and forecasts that Accelus has derived from publicly available information, various industry publications, other published industry sources and internal data and estimates. Industry publications and other published industry sources generally indicate that the information contained therein was obtained from sources believed to be reliable. Internal data and estimates are based upon information obtained from trade and business organizations and other contacts in the markets in which Accelus operates and Accelus' and our management's understanding of industry conditions. Although we believe that such information is reliable, we have not had this information verified by any independent sources. Any estimates underlying such market-derived information and other factors could cause actual results to differ materially from those expressed in the independent parties' estimates and in our estimates.

# INVESTMENT RATIONALE

**Accelus provides a compelling opportunity for CHP**



**Massive Market Opportunity**



**Positive Clinical Outcomes**



**Affordable, Accessible Solution**



**Attractive Growth Profile, High Gross Margins**



**Leverage CHP's Health System Relationships**



**Differentiated Platform Disrupting Minimally Invasive Spine Surgery**



INTEGRITY  
IMPLANTS

FUSION  
ROBOTICS



**OUR MISSION:**

**Accelerating  
Minimally Invasive  
Spine Surgery**

# ACCELUS AT A GLANCE



Improving procedures and outcomes, creating favorable economics, and providing broad accessibility



Clinically-impactful, data-driven, cost-effective,  
**enabling implant technology**



**Transformational robotic solution**, reducing procedural complexity and accelerating growth




**Attractive business model** with pull-through revenue opportunities



Expanding **access** to **care** in the **underserved** MIS spinal surgery market

*The Complete Minimally Invasive Spine Surgery (MIS) Ecosystem*




Providing **broad accessibility**, lowering the cost of care and expanding the market

# TRANSFORMATIONAL ENABLING TECHNOLOGIES

## Robust Portfolio Designed to Enable MIS Spine Surgery

### Innovative Line of MIS Enabling Spinal Implants



### Multidirectional Expandable Interbody Implant Systems



FlareHawk7




TiHawk Platform



Toro-L

### Elegant and Affordable Robotic System



### Transformational Robotic Targeting and Navigation Platform



\*FDA clearance pending or pipeline product under development

©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE.



# SIGNIFICANT MARKET OPPORTUNITY

## Large Spine Market, Opportunities for Disruption


### Spinal Fusion Market Overview

- Large, established U.S. addressable market of \$5.3 billion
- Demographics support continued market growth
- International spinal fusion market of \$3.0 billion
- Opportunity to capture market share with a truly differentiated platform

### KEY TRENDS ACCELERATING GROWTH

- |                      |                         |
|----------------------|-------------------------|
| ✓ MIS Procedures     | ✓ Transition to the ASC |
| ✓ Endoscopic Surgery | ✓ Robotics/Navigation   |
| ✓ Expandable Cages   | ✓ Augmented Reality     |

### Size of Accelus' Current Addressable Market






# SPINAL FUSION SURGERY STATUS QUO

## Opportunities to Address Substantial Unmet Clinical Needs

### MIS Procedures Remain Underpenetrated

MIS techniques offer advantages over open surgical procedures for patients, surgeons and facilities...



Traditional TLIF incision

Minimally invasive TLIF incisions

#### DISADVANTAGES OF OPEN SPINE SURGERY PROCEDURES

- Lengthy procedures
- Significant blood loss
- Extensive soft tissue disruption
- Extended recovery times

...yet only approximately

# 20%

of spinal fusion procedures are currently performed *minimally invasively*

### The Need for Surgical Robotics in Spine

Robotic systems are becoming more widely adopted, given benefits from technological advancements



Accurate

Repeatable

Reliable

Pedicle Screws are misplaced in **10% of cases** performed freehand (without robotic navigation)

#### Limitations of current spine surgery robotic systems

- ⊗ High introductory costs
- ⊗ Steep learning curves to operate
- ⊗ Large footprints within the operating room

# ACCELUS OFFERS KEY ENABLING TECHNOLOGIES

Addressing the Unmet Clinical Needs of Spine Surgery

## Multidirectional Expandable Interbody Platform



Minimal Insertion Profile



Improved Graft Delivery



Significant Fusion Rates

## Enabling Robotic Targeting and Navigation System



Simple



Compact



Affordable

Providing broader accessibility and enabling MIS procedures

# ADDRESSING THE CONSTRAINTS OF MINIMALLY INVASIVE SPINE PROCEDURES

Simpler, safer procedures with more consistent outcomes

- **Reduce** procedural complexity...
- **Expand** visualization...
- **Increase** reproducibility...
- **Reduce** radiation...
- **Address** inefficiency...
- **Reduce** learning curve...

## Access Without Compromise

Adaptive Geometry + Precision Robotics



# ACCELUS OFFERS A TOTAL MIS IMPLANT SOLUTION



Solutions to address the complete procedure

## Innovative Expandable Interbody Platform



Differentiated and cost-effective solutions with high gross margins

## Proprietary Fixation Systems



Proprietary screw technology with substantial growth potential

## Biomaterial Offerings



Allograft comprised demineralized bone matrix (DBM) cortical fibers

## Robotic Targeting and Navigation



Economically attractive robotic solution with sustainable source of consumables revenue

\*Currently under development

\*\* Private labeled product marketed by Accelus

©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE.



# PRODUCT PORTFOLIO

# REVOLUTIONARY MULTIDIRECTIONAL EXPANDABLE IMPLANT TECHNOLOGY




## What is “Adaptive Geometry”?

- Next-generation solution for MIS procedures
- Proprietary expandable cage technology, featuring **multidirectional** expansion of interbody devices

## Why Does it Matter?

- Minimal insertion profile with maximum footprint
- Delivers access through a narrow, neural corridor
- Respects the natural anatomy of the patient
- Designed for improved safety and clinical outcomes\*

### ADAPTIVE™ GEOMETRY in Action



### Adaptive Geometry Integrated Across the Portfolio



\*Zero reported subsidence or device-related adverse events (Coric et al, Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020)

# GAME-CHANGING PORTFOLIO OF SPINAL IMPLANTS WITH **ADAPTIVE GEOMETRY**



## Our Mission

Solve the clinical challenges of MIS procedures through innovation and enabling technology



## The Problem

MIS solutions have focused on surgical techniques improve footprint, but results are mixed and complications remain

**Nerve and Vascular Injuries**

**Subsidence and Non-Union**



## Our Solution

Multidirectional expandable lumbar fusion device, with a minimal insertion profile and maximum expansion



## Clinical Results

Robust performance and significant clinical outcomes

**97.4%** Fusion Rate\*

**0**

Device-Related  
Adverse Effects\*

**0%**

Subsidence\*

\*One year follow up study found 96.6% of patients and 97.4% of levels were considered fused, and there were zero cases of device subsidence exceeding 25% of the device height, per Coric et al, Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020





Broad service offering to address MIS needs

## FlareHawk Family of Spinal Fusion Cages Designed For:

- 
**Minimal Insertion Profile**  
 Minimizing neural retraction
- 
**Multiplanar Expansion**  
 Wide footprint with no compromise
- 
**Improved Graft Delivery**  
 Open architecture for continuous graft delivery





7mm profile  
Endoscopically Assisted TLIF





9mm profile  
expanding to 14 x 14mm





11mm profile  
expanding to 17 x 14mm





Titanium Coated  
TiHawk7, 9, 11\*

**11,000+**  
Cages Implanted

**3**  
Clinical Studies

**97.4%**  
Fusion Rate\*

**0%**  
Subsidence\*

**0**  
Device-Related Adverse Events\*


\* Coric et al, Bidirectional Expandable Technology for Transforaminal or Posterior Lumbar Interbody Fusion: A Retrospective Analysis of Safety and Performance, Int J Spine Surg. 2020

\*\*FlareHawk11 and TiHawk11 anticipated to be available in Q1 2022




### Open

Robust implants and instrumentation to address complex pathology



### MIS

Elegant design optimized for seamless percutaneous approach



### Cortical

Modular tulip heads with slim profiles facilitate a mid-line approach



### Telescopic Screw Technology

Proprietary screw technology designed to reduce current frustrations and complications with posterior fixation. Complements robotics platforms.



An all-in-one screw delivery system designed to reduce instruments, surgical steps, and radiation. Allows for repositioning of screw trajectory without compromising screw purchase.



\*Periscope™ under development

# TRANSFORMATIONAL ROBOTIC TARGETING AND NAVIGATION SYSTEM

Optimized for daily use, with a  
small 30" x 30" footprint

Easier to use than alternative  
robotic and navigation system

One-third to one-fourth of the  
cost of alternative systems



# ROBOTIC TARGETING AND NAVIGATION SYSTEM



❓ **The Problem:** Surgeons that need robotics are in facilities that **can't afford them**

💡 **Our Solution:**

✓ **Cost-Effective Without Compromise**

Precision navigation robotic targeting system for spine surgery, offered at a fraction of the price of the competition

✓ **Attractive Surgeon Economics**

Rapid system positioning with quick and easy set-up and breakdown allowing surgeons to treat more patients

✓ **Enhanced Ease of Use**


Constructed to streamline workflows with a simplified, intuitive design, minimizing surgeon training requirements

✓ **Platform Built for Adaptability**

Technology designed to expand applications to other spinal surgery procedures



# ROBOTIC, ENABLED, MINIMALLY INVASIVE TARGETING AND NAVIGATION SYSTEM



## EXTRAORDINARY FEATURES...

**SMALLER**

TABLE MOUNTED SYSTEM  
WITH A NEARFIELD CAMERA

**FASTER**

~35% REDUCTION IN PROCEDURE TIME  
COMPARED TO THE COMPETITION\*

**MORE AFFORDABLE**

PRICED AT A FRACTION OF THE COST  
COMPARED TO THE COMPETITION

**...WITHOUT COMPROMISE**

\*Soliman et al, Accuracy and Efficiency of Fusion Robotics Versus Mazor-X in Single-Level Lumbar Pedicle Screw Placement, Cureus Journal of Medical Science. 2021





## GLOBAL PATENT PROTECTION

**26** US PATENTS

**26** US APPS

**19** INT'L PATENTS

**36** INT'L APPS

**Patent Duration:**  
2033-2039

## ROBUST PORTFOLIO WITH INNOVATIVE PRODUCT PIPELINE

- 510(k) Pathway:
- FlareHawk9
- LineSider
- FlareHawk7
- TiHawk
- Robotic System
- Toro-L
- Toro-P (2022\*)
- Zform (2022\*)
- 2-D Robotic System (2022\*)
- Toro-A (2023\*)

## PUBLISHED CLINICAL DATA

**3** PEER REVIEWED, MULTI-CENTER STUDIES ON FLAREHAWK

**1** PEER REVIEWED ROBOTIC NAVIGATION STUDY

**8** CLINICAL STUDIES IN PROCESS & PROPOSED

# PEER-REVIEWED CLINICAL DATA



## FlareHawk Clinical Studies

- Published in International Journal of Spine Surgery (IJSS)
- Three retrospective, peer-reviewed studies
- Fusion rates commensurate with PLIF and TLIF procedures, minimal complications

## Compendium of Published Peer-Reviewed FlareHawk Data

## Navigation and Robotic Targeting System

- Published in Cureus Journal of Medical Science
- Comparison against most commonly used spine robot platform (Mazor-X)
- Significantly shorter procedure workflow duration (better efficiency)

## Current in-process and proposed clinical research includes:

- Pressure distribution comparison against commonly used interbody devices
  - FlareHawk prospective EU
  - Robotic navigation IRB submission
  - LineSider anti-skiving
- Robotic navigation endoscopic
  - MIS spondy TLIF
  - Robotic navigation time reduction
  - Robotic navigation Kambin's targeting



Proven workflow efficiencies and time savings when utilizing Accelus' Robotic system



# PRODUCT PIPELINE & ASC OPPORTUNITY

# JOURNEY OF INNOVATION

Established History of Development With Robust Product Pipeline



\*FDA clearance pending or pipeline product under development

# ACCELUS' NEXT ADAPTIVE GEOMETRY OFFERING





## EXPANDABLE PLATFORM



### Adaptive Geometry Reimagined

Expands wide first under minimal load → then lifts with wide footprint



Lateral (LLIF)  
2022



Posterior (PLIF / TLIF)  
2023



Anterior (ALIF)  
2023

**FACILITATES  
ENTRANCE INTO  
LATERAL AND  
ANTERIOR MARKETS**

### Key Features and Benefits of Toro Platform



Inserted with  
minimal profile



3D Printed  
endplates



Post-packed  
with bone graft



Infinitely  
expandable




# AMBULATORY SURGERY CENTER (ASC) MARKET

## GROWING ASC OPPORTUNITY

- Spine procedures increasingly moving to ambulatory surgery centers
- 86% of spine surgeons expect to use ASCs\*
- Spine surgery is considered among the most profitable and cost-effective ASC procedure
- Reimbursement tailwinds expected to continue
- Win-win-win for patients, payers and providers

## ENABLING TECHNOLOGIES DRIVING ASC ADOPTION



\*Van Biesen & Johnson, Ambulatory Surgery Center Growth Accelerates: Is Medtech Ready?, Bain & Company. 2019

\*\*Soliman et al, Accuracy and Efficiency of Fusion Robotics Versus Mazor-X in Single-Level Lumbar Pedicle Screw Placement, Cureus Journal of Medical Science. 2021

# GROWTH AND FINANCIALS

# GROWTH OPPORTUNITIES






# FINANCIAL HIGHLIGHTS



## Revenue Forecast

5-year Growth  
Expectations\*



**\$27.5**  
MILLION

**2021E  
REVENUE**



**\$81.0**  
MILLION

**2023E  
REVENUE**



GROWING AT  
**60%**

**2020 to 2025  
FORECASTED  
CAGR**



**80%+**

**Historical Non-GAAP  
GROSS MARGIN\*\***

\*Revenue projections rounded to the nearest million

\*\*Gross margin based upon Adjusted Gross Profit, a non-GAAP financial measure adjusting gross profit for inventory write-offs; refer to *Management's Discussion and Analysis of Financial Condition and Results of Operations of Integrity Implants Inc.* within the S-4 filed by CHPM on February 15, 2022 and the appendix for a reconciliation of GAAP and non-GAAP financial metrics.



# INVESTMENT TAKEAWAYS



**Accelerating  
Minimally Invasive  
Spine Surgery**



# APPENDIX I: FINANCIAL DETAIL

# TRANSACTION OVERVIEW

## Source of Funds

Accelus Rollover Equity	\$413.5
Convertible Note / Series D Investments <sup>1</sup>	6.2
Proceeds from Trust Account	187.1
<b>Total Sources</b>	<b>\$606.8</b>

## Pro Forma Valuation

Share Price	\$10.00
Pro Forma Shares Outstanding	66.4
<b>Equity Value</b>	<b>\$663.8</b>
(+) Debt <sup>2</sup>	\$13.6
(-) Pro Forma Cash <sup>2</sup>	(\$171.8)
<b>Enterprise Value</b>	<b>\$505.6</b>
<b>EV / 2022E Revenue</b>	<b>10.5x</b>
<b>EV / 2023E Revenue</b>	<b>6.2x</b>

Note: Estimated SPAC Cash in Trust assumes no redemptions. Excludes impact of 1.9 million sponsor earnout shares vesting ratably at \$13.00 and \$16.00. Excludes impact of 15.0 million public warrants and 8.0 million sponsor warrants (including 1.6 million transferred to Accelus shareholders and 2.0 million subject to earnout ratably at \$13.00 and \$16.00) struck at \$11.50. Includes 2.1 million sponsor shares and 2.2 million sponsor warrants subject to forfeiture if cash delivered is between \$150 million and \$75 million after redemptions. Estimated SPAC Cash in Trust amount subject to change.

1. Includes \$3.1 million of funding for the Monthly Contributions in connection with the Extension within Convertible Notes and Affiliated Series D Investments. Thus, the balance is not included in the Proceeds from Trust Account.


2. Reflects pro forma cash and debt figures set forth in the Unaudited Pro Forma Condensed Combined Financial Statements disclosed in the S-4 filing. Actual pro forma cash balances subject to change.

©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE.




















## Use of Funds

Accelus Rollover Equity	\$413.5
Cash to Balance Sheet	155.3
Extension Premium Payments	3.1
Estimated Transaction Costs	34.9
<b>Total Uses</b>	<b>\$606.8</b>

## Illustrative Pro Forma Ownership



# COMPELLING VALUATION

		EV / Revenue 2022E	EV / Revenue 2023E	Revenue CAGR '21 – '23
High Growth Med-Tech	       	11.9x	9.2x	37%
Premium Spine & Orthopedics	    	7.3x	6.0x	21%
Enabling Robotic Technology	 	14.7x	10.3x	46%
<b>Accelus</b>		<b>10.5x</b>	<b>6.2x</b>	<b>72%</b>
<div> <div> <b>Precedent Robotic Transactions</b> </div> <div>  = \$1.6 billion (2013) EV / FTM Rev. = 10.6x                 </div> <div>  = \$1.6 billion (2018) EV / FTM Rev. = 20.7x                 </div> <div>  = \$1.1 billion (2019) EV / FTM Rev. = 44.5x                 </div> </div>				


Source: Wall Street research, company filings and S&P Capital IQ; market data as of March 9, 2022



# HIGH VISIBILITY TO 2023 REVENUE GROWTH

## Commentary

- Sales of existing products lines are anticipated to be the largest contributor to growth, largely driven by pull-through sales
- Robot Pull-Through revenue is expected to account for 20% of total sales by 2025



A

## Core Product Growth

- Comprised of our existing lines including:
  - FlareHawk / TiHawk\*
  - LineSider Fixation (pedicle screws)
  - Biologics

B

## Pipeline Products

- Comprised of our near-term anticipated line extensions:
  - Toro Lateral
  - Toro ALIF
  - Toro PLIF/TLIF

C

## Robot Revenue

- Comprised of robot hardware sales and revenue generated from consumables

D

## Pull-Through Sales

- Comprised of sales from Core Products driven by robot placements
  - Direct pull-through of LineSider Fixation systems used in conjunction with robot
  - Indirect pull-through of interbody devices through cross-sale opportunities

\*Includes new iterations of FlareHawk and TiHawk products



# RESULTS OF OPERATIONS



	Year Ended December 31,		Year-to-Date September 30,	
(\$ in thousands)	2019	2020	2020	2021
<b>Net Revenue</b>	<b>\$16,642</b>	<b>\$16,871</b>	<b>\$11,773</b>	<b>\$17,901</b>
Cost of Revenue	3,013	4,479	3,269	4,338
<b>Gross Profit</b>	<b>13,629</b>	<b>12,392</b>	<b>8,504</b>	<b>13,563</b>
Non-GAAP Gross Profit	13,849	13,689	9,519	14,399
Non-GAAP Gross Margin	83%	81%	81%	80%
<u>Operating Expenses:</u>				
Selling, General and Administrative	18,992	20,599	14,643	24,162
Research and Development	2,797	3,214	2,312	3,042
Amortization of Intangible Assets	707	707	530	1,079
Total Operating Expenses	22,496	24,520	17,485	28,283
<b>Loss from Operations</b>	<b>(8,867)</b>	<b>(12,128)</b>	<b>(8,981)</b>	<b>(14,720)</b>
Interest and Other Income (Expense)	(904)	(288)	(215)	(4,552)
Income Tax (Provision) Benefit	-	-	-	2,977
<b>Net Loss</b>	<b>(\$9,771)</b>	<b>(\$12,416)</b>	<b>(\$9,196)</b>	<b>(\$16,295)</b>
<b>Non-GAAP Adjusted EBITDA</b>	<b>(\$6,080)</b>	<b>(\$8,634)</b>	<b>(\$6,381)</b>	<b>(\$11,436)</b>





# NON-GAAP FINANCIAL MEASURES




	Year Ended December 31,		Year-to-Date September 30,	
(\$ in thousands)	2019	2020	2020	2021
<b>Net Loss, as reported</b>	<b>(\$9,771)</b>	<b>(\$12,416)</b>	<b>(\$9,196)</b>	<b>(\$16,295)</b>
<u>Adjustments:</u>				
Add: Interest expense, net	332	288	215	3,737
Add: Amortization of intangible assets	707	707	530	1,079
Add: Depreciation	607	1,247	870	1,471
Less: Income tax benefit	-	-	-	(2,977)
<b>EBITDA</b>	<b>(\$8,125)</b>	<b>(\$10,174)</b>	<b>(\$7,581)</b>	<b>(\$12,985)</b>
<u>Adjustments:</u>				
Add: Transaction-related expenses	-	-	-	1,405
Add: Inventory write-off adjustments	220	1,297	1,015	836
Add: Loss on debt extinguishment	557	-	-	93
Add: Stock-based compensation	1,268	243	185	298
Less: PPP loan forgiveness	-	-	-	(1,083)
<b>Non-GAAP Adjusted EBITDA</b>	<b>(\$6,080)</b>	<b>(\$8,634)</b>	<b>(\$6,381)</b>	<b>(\$11,436)</b>
<b>Gross Profit, as reported</b>	<b>\$13,629</b>	<b>\$12,392</b>	<b>\$8,504</b>	<b>\$13,563</b>
Inventory write-off adjustment	220	1,297	1,015	836
<b>Non-GAAP Adjusted Gross Profit</b>	<b>\$13,849</b>	<b>\$13,689</b>	<b>\$9,519</b>	<b>\$14,399</b>
<i>Non-GAAP Gross Margin</i>	<i>83%</i>	<i>81%</i>	<i>81%</i>	<i>80%</i>



# APPENDIX II: COMMERCIAL STRATEGY

# ATTRACTIVE BUSINESS MODEL


Enabling technology drives product pull-through



# ESTABLISHED COMMERCIAL FOOTPRINT

## Strong Commercial Infrastructure

- ✓ Dedicated internal sales force
- ✓ External distributor network
- ✓ Growing talent pool
- ✓ Regionally focused
- ✓ HQ in Palm Beach Gardens, FL
- ✓ Centers of excellence accessible to our entire customer base
- ✓ Wide breadth of hospital approvals




## Commercialization Strategy

- ✓ Rapidly expand sales team
- ✓ Grow direct sales force in targeted markets
- ✓ Continue to build capital sales infrastructure
- ✓ Invest in surgeon training and education programs
- ✓ Increase procedural capture
- ✓ Focus on ASC and enterprise level growth
- ✓ Path to expanding spine procedural offerings to drive exclusivity

## Focused Strategy to Accelerate Growth

# LUMBAR INTERBODY MARKET BY APPROACH



## MARKET FOR INTERBODY SPINAL FUSION DEVICES

- Total U.S. Spinal Fusion market is **\$7.3 billion+**
- ~250,000 lumbar spinal fusion procedures utilize interbody devices
- Accelus' proprietary products currently only address posterior procedures accounting for ~66% of all lumbar interbody procedures


## SUBSTANTIAL OPPORTUNITY FOR GROWTH...

Reflects percentage of total market value (\$) by surgical approach

©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE.



# LUMBAR INTERBODY MARKET BY APPROACH



## ROBUST PIPELINE TO FILL OUT INTERBODY PORTFOLIO\*

- Toro expands Accelus' market opportunity



## ADDITIONAL OPPORTUNITIES

- More than 350,000 Cervical Fusion procedures performed annually
- Robot placements positioned to drive LineSider (pedicle screw) sales, which represents the largest segment of the spinal fusion market

Reflects percentage of total market value (\$) by surgical approach

\*Does not reflect full product pipeline

©2022 ACCELUS. ALL RIGHTS RESERVED. CONFIDENTIAL. DO NOT DISTRIBUTE.

# APPENDIX III: LEADERSHIP TEAM



# WORLD-CLASS SPINE LEADERSHIP



**CHRIS WALSH**  
CEO & Co-Founder



**ALEX LUKIANOV**  
Chairman



**KEVIN WILLIAMSON**  
CFO



**ANDREW WOLF**  
CSO



**WYATT GEIST**  
CIO



**BLAKE STONE**  
General Counsel



**KEVIN MCGANN**  
President



**BRAD CLAYTON**  
CTO



# CHAIRMAN OF CHP MERGER CORP



**JOSEPH SWEDISH**

Chairman  
CHP Merger Corp. (CHPM)



*“ With an extensive 40+ year background as an Executive and Board member in both the health system provider and payor world, I uniquely understand the challenges that face the industry and the technologies with the strong potential to solve them. As such, I look forward to bringing my experience and network to Accelus.*

*We are excited about the opportunity to merge with Accelus – a company that is uniquely equipped to transform the minimally invasive spine surgery segment with an **innovative portfolio of technologies** and **revolutionary robotics platform**.*

*Since inception, CHPM has sought opportunities to partner with companies that are disruptors of the status quo through working to lower costs and expand access to quality healthcare. Accelus is not only a leader in this regard, but we are confident they are poised to become a leading innovator in the spinal health market. We’ve been so impressed with Chris Walsh and his team’s mission and sense of purpose.*

*We are thrilled to partner with Accelus on their mission to **redefine minimally invasive surgery as the new standard of care** in spine and have already begun to leverage our industry expertise and established relationships with health systems to help realize this strategic vision.*

*”*